drugset / Trial / NCT03877237

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

NCT03877237 ↗

Phase 3 Completed 313 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)

Timeline

Start
2019-04-09
Primary completion
2020-03-07
Completion
2020-03-07

Outcome

Mixed primary results

registry analysis (superiority test); Dapa 10mg vs Placebo; p = 0.02164; Hodges-Lehmann median diff. vs placebo 4.23 (95% CI 0.96 to 8.22) NCT03877237 ↗

registry analysis (superiority test); Dapa 10mg vs Placebo; p = 0.05842; Hodges-Lehmann median diff. vs placebo 4.17 (95% CI 0.03 to 8.33) NCT03877237 ↗

registry analysis (superiority test); Dapa 10mg vs Placebo; p = 0.68626; Hodges-Lehmann median diff. vs placebo 3.2 (95% CI -6.5 to 13.0) NCT03877237 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral